Halozyme Therapeutics, Inc. (HALO)

Market Cap	7.51B
Revenue (ttm)	1.02B
Net Income (ttm)	444.09M
Shares Out	123.53M
EPS (ttm)	3.43
PE Ratio	17.73
Forward PE	12.16
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,147,965
Open	60.11
Previous Close	60.57
Day's Range	59.53 - 61.85
52-Week Range	37.97 - 66.00
Beta	1.32
Analysts	Buy
Price Target	62.89 (+3.4%)
Earnings Date	May 6, 2025

About HALO

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally. The company’s products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the disper...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1998
• Country: United States
• Stock Exchange: NASDAQ
• Ticker Symbol: HALO
• Website: https://halozyme.com

Financial Performance

In 2024, Halozyme Therapeutics's revenue was $1.02 billion, an increase of 22.44% compared to the previous year's $829.25 million. Earnings were $444.09 million, an increase of 57.71%.

Analyst Forecast

According to 9 analysts, the average rating for HALO stock is "Buy." The 12-month stock price forecast is $62.89, which is an increase of 3.40% from the latest price.

Price Target

$62.89

(3.40% upside)

Analyst Consensus: Buy